Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04620733
Registration number
NCT04620733
Ethics application status
Date submitted
4/11/2020
Date registered
9/11/2020
Date last updated
29/09/2023
Titles & IDs
Public title
RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Query!
Scientific title
RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Query!
Secondary ID [1]
0
0
CB8025-32048
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Primary Biliary Cholangitis
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Seladelpar 10 mg
Treatment: Drugs - Placebo
Treatment: Drugs - Seladelpar 5 mg
Experimental: Seladelpar 10 mg -
Placebo Comparator: Placebo -
Experimental: Seladelpar 5 mg -
Treatment: Drugs: Seladelpar 10 mg
Seladelpar 10 mg one capsule daily for double-blind period, for a duration of up to 12 months
Treatment: Drugs: Placebo
One capsule daily for double-blind period, for a duration of up to 12 months
Treatment: Drugs: Seladelpar 5 mg
If down-titration needed, one capsule daily for double-blind period, for a duration of up to 12 months
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Composite endpoint of ALP and total bilirubin
Query!
Assessment method [1]
0
0
ALP < 1.67× ULN,
= 15% decrease in ALP, and
Total bilirubin =1.0× ULN
Query!
Timepoint [1]
0
0
12 months
Query!
Secondary outcome [1]
0
0
Normalization of ALP
Query!
Assessment method [1]
0
0
Proportion of subjects with ALP =1.0× ULN
Query!
Timepoint [1]
0
0
12 months
Query!
Secondary outcome [2]
0
0
Change in baseline numerical rating scale (NRS)
Query!
Assessment method [2]
0
0
Weekly averaged pruritus NRS in subjects with baseline NRS =4. The NRS is a scale of 0 (no itching) to 10 (worst imaginable itching)
Query!
Timepoint [2]
0
0
6 months
Query!
Eligibility
Key inclusion criteria
1. Must have given written informed consent (signed and dated) and any authorizations
required by local law
2. 18 to 75 years old (inclusive)
3. Male or female with a definitive diagnosis of PBC
4. UDCA for the past 12 months (stable dose for >3 months prior to screening) OR
intolerant to UDCA (last dose of UDCA >3 months prior to screening)
5. Laboratory parameters measured by the Central Laboratory at screening:
1. ALP =1.67× ULN
2. Aspartate aminotransferase (AST) =3× ULN
3. ALT =3× ULN
4. Total bilirubin =2× ULN
5. Estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m2 (calculated by the
Modification of Diet in Renal Disease study equation)
6. International normalized ratio (INR) below 1.1× ULN For subjects on
anticoagulation therapy, INR must be maintained in the range required for
prophylaxis for their specific disease.
7. Platelet count =100×103/µL
NOTE: PT, INR, and platelets can be performed locally at the Screening Visit, if
deemed necessary by the investigator after consultation with the medical monitor, in
cases where centrally read samples are deemed invalid.
6. Females of reproductive potential must use at least 1 barrier contraceptive and a
second effective birth control method during the study and for at least 90 days after
the last dose. Male subjects who are sexually active with female partners of
reproductive potential must use barrier contraception, and their female partners must
use a second effective birth control method during the study and for at least 90 days
after the last dose
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Previous exposure to seladelpar (MBX-8025).
2. A medical condition other than PBC that, in the investigator's opinion, would preclude
full participation in the study (e.g., cancer) or confound its results (e.g., Paget's
disease, any active infection).
3. Advanced PBC as defined by the Rotterdam criteria (albumin below the lower limit of
normal AND total bilirubin above 1.0× ULN)
4. Presence of clinically important hepatic decompensation, including the following:
1. History of liver transplantation, current placement on liver transplantation
list, or current Model for End-Stage Liver Disease (MELD) score =12. For subjects
on anticoagulation medication, evaluation of the baseline INR, in concert with
their current dose adjustments of their anticoagulant medication, will be taken
into account when calculating the MELD score. This will be done in consultation
with the medical monitor.
2. Complications of portal hypertension, including known esophageal varices, history
of variceal bleeds or related interventions (ege.g., transjugular intrahepatic
portosystemic shunt placement), ascites, and hepatic encephalopathy.
3. Cirrhosis with complications, including history or presence of spontaneous
bacterial peritonitis, hepatocellular carcinoma, or hepatorenal syndrome.
5. Other chronic liver diseases:
1. Current features of AIH as determined by the investigator based on
immunoserology, liver biochemistry, or historic confirmed liver histology.
2. PSC determined by the presence of diagnostic cholangiographic findings.
3. History or clinical evidence of alcoholic liver disease.
4. History or clinical evidence of alpha-1-antitrypsin deficiency.
5. History of biopsy confirmed NASH.
6. History or evidence of Gilbert's syndrome with elevated total bilirubin.
7. History or evidence of hemochromatosis.
8. Hepatitis B, defined as the presence of hepatitis B surface antigen.
9. Hepatitis C, defined as the presence of hepatitis C virus ribonucleic acid.
10. History, evidence, or high suspicion of hepatobiliary malignancy based on
imaging, screening laboratory values, and/or clinical symptoms.
6. Known history of human immunodeficiency virus (HIV) or positive antibody test at
screening
7. Clinically important alcohol consumption, defined as more than 2 drink units per day
(equivalent to 20 g) in women and 3 drink units per day (equivalent to 30 g) in men,
or inability to quantify alcohol intake reliably.
8. History of malignancy diagnosed or treated, actively or within 2 years, or ongoing
evaluation for malignancy; localized treatment of squamous or noninvasive basal cell
skin cancers and cervical carcinoma in situ is allowed if appropriately treated prior
to screening.
9. Treatment with obeticholic acid (OCA) or fibrates (e.g., bezafibrate, fenofibrate,
elafibranor, lanifibranor, pemafibrate, saroglitizar) 6 weeks prior to screening
10. Treatment with colchicine, methotrexate, azathioprine, or long-term systemic
corticosteroids (>2 weeks) during 2 months prior to screening
11. Treatment with anti-pruritic drugs (e.g., cholestyramine, naltrexone, rifampicin,
sertraline, or any experimental approach) must be on a stable dose within 1 month
prior to screening
12. Treatment with any other investigational therapy or device within 30 days or within 5
half-lives, whichever is longer, prior to screening
13. For females, pregnancy or breastfeeding
14. Any other condition(s) that would compromise the safety of the subject or compromise
the quality of the clinical study, as judged by the investigator
15. Immunosuppressant therapies
16. Other medications that effect liver or GI functions, such as absorption of medications
or the roux-en-y gastric bypass procedure, may be prohibited and should be discussed
with the medical monitor on a case-by-case basis.
17. Active COVID-19 infection during Screening.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
21/04/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
11/08/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
193
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Concord Repatriation General Hospital - Concord
Query!
Recruitment hospital [2]
0
0
Royal Brisbane & Women's Hospital - Herston
Query!
Recruitment hospital [3]
0
0
Alfred Hospital - Melbourne
Query!
Recruitment hospital [4]
0
0
The Royal Melbourne Hospital - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [2]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [3]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [4]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Louisiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Minnesota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Mississippi
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Missouri
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New York
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
North Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Ohio
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Pennsylvania
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Tennessee
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Texas
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Virginia
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Washington
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Buenos Aires
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Caba
Query!
Country [24]
0
0
Austria
Query!
State/province [24]
0
0
Wels
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Antwerpen
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Liège
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Oost-Vlaanderen
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Vlaams-Brabant
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Ontario
Query!
Country [30]
0
0
Chile
Query!
State/province [30]
0
0
Coquimbo
Query!
Country [31]
0
0
Chile
Query!
State/province [31]
0
0
Los Ríos
Query!
Country [32]
0
0
Chile
Query!
State/province [32]
0
0
Valparaíso
Query!
Country [33]
0
0
Czechia
Query!
State/province [33]
0
0
Ostrava
Query!
Country [34]
0
0
Denmark
Query!
State/province [34]
0
0
Aalborg
Query!
Country [35]
0
0
Denmark
Query!
State/province [35]
0
0
Hvidovre
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Grenoble
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Lyon
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Paris
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Nordrhein-Westfalen
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Saarland
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Erlangen
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Frankfurt am main
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Hamburg
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Herne
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Leipzig
Query!
Country [46]
0
0
Greece
Query!
State/province [46]
0
0
Attiki
Query!
Country [47]
0
0
Greece
Query!
State/province [47]
0
0
Larissa
Query!
Country [48]
0
0
Hungary
Query!
State/province [48]
0
0
Budapest
Query!
Country [49]
0
0
Hungary
Query!
State/province [49]
0
0
Kaposvár
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Jerusalem
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Ramat Gan
Query!
Country [52]
0
0
Israel
Query!
State/province [52]
0
0
Tel Aviv
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
MB
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Ancona
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Bologna
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Firenze
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Padova
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Palermo
Query!
Country [59]
0
0
Korea, Republic of
Query!
State/province [59]
0
0
Busan Gwangyeogsi
Query!
Country [60]
0
0
Korea, Republic of
Query!
State/province [60]
0
0
Gyeonggido
Query!
Country [61]
0
0
Korea, Republic of
Query!
State/province [61]
0
0
Busan
Query!
Country [62]
0
0
Korea, Republic of
Query!
State/province [62]
0
0
Daegu
Query!
Country [63]
0
0
Korea, Republic of
Query!
State/province [63]
0
0
Gyeonggi-do
Query!
Country [64]
0
0
Korea, Republic of
Query!
State/province [64]
0
0
Seoul
Query!
Country [65]
0
0
Korea, Republic of
Query!
State/province [65]
0
0
Soeul
Query!
Country [66]
0
0
Mexico
Query!
State/province [66]
0
0
Ciudad de Mexico
Query!
Country [67]
0
0
Mexico
Query!
State/province [67]
0
0
Metepec
Query!
Country [68]
0
0
Mexico
Query!
State/province [68]
0
0
Mexico City
Query!
Country [69]
0
0
Mexico
Query!
State/province [69]
0
0
Monterrey
Query!
Country [70]
0
0
New Zealand
Query!
State/province [70]
0
0
Canterbury
Query!
Country [71]
0
0
New Zealand
Query!
State/province [71]
0
0
Otago
Query!
Country [72]
0
0
Poland
Query!
State/province [72]
0
0
Katowice
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Myslowice
Query!
Country [74]
0
0
Romania
Query!
State/province [74]
0
0
Bucharest
Query!
Country [75]
0
0
Russian Federation
Query!
State/province [75]
0
0
Moscow
Query!
Country [76]
0
0
Russian Federation
Query!
State/province [76]
0
0
Saint Petersburg
Query!
Country [77]
0
0
Russian Federation
Query!
State/province [77]
0
0
Samara
Query!
Country [78]
0
0
Russian Federation
Query!
State/province [78]
0
0
Stavropol
Query!
Country [79]
0
0
Russian Federation
Query!
State/province [79]
0
0
Ulyanovsk
Query!
Country [80]
0
0
Spain
Query!
State/province [80]
0
0
Barcelona
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Cantabria
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Malaga
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Madrid
Query!
Country [84]
0
0
Switzerland
Query!
State/province [84]
0
0
Zürich
Query!
Country [85]
0
0
Turkey
Query!
State/province [85]
0
0
Ankara
Query!
Country [86]
0
0
Turkey
Query!
State/province [86]
0
0
Istanbul
Query!
Country [87]
0
0
Turkey
Query!
State/province [87]
0
0
Izmir
Query!
Country [88]
0
0
Ukraine
Query!
State/province [88]
0
0
Kharkiv
Query!
Country [89]
0
0
Ukraine
Query!
State/province [89]
0
0
Kyiv
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Devon
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Hampshire
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
London, City Of
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Nottinghamshire
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Oxfordshire
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Birmingham
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
Hull
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
CymaBay Therapeutics, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To evaluate the treatment effect of seladelpar on composite biochemical improvement in
cholestasis markers based on ALP and total bilirubin and to evaluate the safety of seladelpar
over 12 months of treatment compared to placebo
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04620733
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04620733
Download to PDF